1084-1085 / 1578
Overall survival
Progression survival
Ruers T, JNCI 2917
Median follow up: 9.7 years. 77% patients had died (65.0% CMT vs 90% systemic
treatment arm)
Significant difference in OS for CMT arm (HR 0.58, 95% CI 0.38 to 0.88, P .01)
Median OS of 45.6 months in CMT arm versus 40.5 months in standard arm
3-,
5-
and
8-
year OS were 57%,
43%
and
36%
in CMT arm versus 55%,
30%
and
9%
in the systemic treatment arm
Unresectable CRLM Local treatment